T-DM1 shows across-board benefits as EMILIA breast cancer data unveiled
This article was originally published in Scrip
Women treated with Genentech's antibody-drug conjugate T-DM1 (trastuzumab emtansine) lived nearly six months longer than HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine in the Phase III EMILIA study used to support applications for regulatory approval of the closely watched second-line therapy.
You may also be interested in...
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.